NRXP
NRX Pharmaceuticals, Inc.Marquee-fund ownership over time
This quarter's activity
New positions opened
None.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Two Sigma Investments | Q2 2025 | Q2 2026 | → $3.28 | +37% |
| Point72 Asset Management | Q1 2026 | Q2 2026 | → $3.28 | +82% |
| Renaissance Technologies | Q4 2025 | Q1 2026 | → $1.73 | -33% |
| Citadel Advisors | Q3 2025 | Q4 2025 | → $2.49 | -7% |
| Millennium Management | Q1 2025 | Q2 2025 | → $2.40 | -16% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at NRX Pharmaceuticals, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Feb 17, 2026 — the most recent Form 4 on file — not from today.
- Form 40001437749-26-004426Feb 17, 2026
- Form 40001415889-25-024084Sep 10, 2025
- Form 40001415889-25-024083Sep 10, 2025
- Form 40001415889-25-024082Sep 10, 2025
- Form 40001415889-25-024081Sep 10, 2025
- Form 40001415889-25-003585Feb 11, 2025
- Form 40001415889-24-029694Dec 18, 2024
- Form 40001415889-23-013139Sep 11, 2023
- Form 40001415889-23-013137Sep 11, 2023
- Form 40001104659-23-094815Aug 24, 2023
- Form 40001104659-23-094406Aug 23, 2023
- Form 40001415889-22-012654Dec 19, 2022
- Form 40001415889-22-012652Dec 19, 2022
- Form 4/Aamend0001415889-22-012650Dec 19, 2022
- Form 40001415889-22-012324Dec 9, 2022
Fundamentals
XBRL · NRX Pharmaceuticals, Inc.Annual figures sourced directly from NRX Pharmaceuticals, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for NRX Pharmaceuticals, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KFORM 8-KJun 4, 2026
- 8-KFORM 8-KJun 2, 2026
- 10-QFORM 10-QMay 15, 2026
- 8-KFORM 8-KMar 24, 2026
- 10-KFORM 10-KMar 23, 2026
- DEF 14AFORM DEF 14AFeb 23, 2026
- 8-KFORM 8-KFeb 17, 2026
- 8-KFORM 8-KFeb 17, 2026
- 8-KFORM 8-KFeb 2, 2026
- 8-KFORM 8-KJan 16, 2026
- 8-KFORM 8-KDec 29, 2025
- S-3/AFORM S-3/ADec 12, 2025
- 8-KFORM 8-KNov 26, 2025
- 8-K/AFORM 8-K/ANov 21, 2025
- 10-QFORM 10-QNov 14, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Point72 Asset Management | Q1 2026 | Q2 2026 | $1.80 | $3.28 | +82% |
| Renaissance Technologies | Q4 2025 | Q1 2026 | $2.59 | $1.73 | -33% |
| Citadel Advisors | Q3 2025 | Q4 2025 | $2.67 | $2.49 | -7% |
| Two Sigma Investments | Q2 2025 | Q2 2026 | $2.40 | $3.28 | +37% |
| Millennium Management | Q1 2025 | Q2 2025 | $2.85 | $2.40 | -16% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.